Cite
HARVARD Citation
Kremer, J. et al. (2016). A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy. Arthritis & rheumatology. 68 (12), pp. 2867-2877. [Online].